BWA
ACAD icon

Basecamp Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Basecamp Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83K Hold
112
– – ﹤0.01% 1292
2026
Q1 		$2.49K Sell
112
-95
-46% -$2.27K ﹤0.01% 1351
2025
Q4 		$5.53K Buy
+207
New +$4.95K ﹤0.01% 1127

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Basecamp Wealth Advisors's ACAD Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 112 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

Basecamp Wealth Advisors first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.53K in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Basecamp Wealth Advisors held 112 shares of Acadia Pharmaceuticals worth $2.83K as of Q2 2026.
  • Basecamp Wealth Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1292 holding.
  • Basecamp Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Acadia Pharmaceuticals position peaked at $5.53K in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.